COVID-19 pill shows more promise in reducing risk of hospitalization

The antiviral pill molnupiravir reduced the risk of COVID-19 hospitalization by 65% in a new study by Indian researchers that offered stronger results than previous research about the drug’s effectiveness.

The study, led by a researcher at the Chennai Antiviral Research and Treatment Clinical Research Site, split 1,218 Indian adults infected with the coronavirus and experiencing mild symptoms into comparably sized groups.

Only 1.5% of the group that received the pill required hospitalization, compared with 4.3% of the group that didn’t receive the pill.